1 Heart age estimated using explainable advanced electrocardiography Thomas Lindow, MD, PhD<sup>1,2,3\*</sup>, Israel Palencia-Lamela, 1,4\* Todd T Schlegel, MD<sup>5,6</sup>, 2 Martin Ugander, MD, PhD<sup>1,5</sup> 3 1. Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia 4 2. Department of Clinical Physiology, Research and Development, Växjö Central Hospital, 5 Region Kronoberg, Sweden 6 3. Clinical Physiology, Clinical Sciences, Lund University, Sweden 4. Davidson College, Davidson, North Carolina, USA 9 5. Department of Clinical Physiology, Karolinska Institutet, and Karolinska University 10 Hospital, Stockholm, Sweden 11 6. Nicollier-Schlegel SARL, Trélex, Switzerland 12 13 \*Shared first-authorship by equal contribution 14 15 **Fundings:** TL is currently under the support of postdoctoral research grants from The 16 Swedish Heart-Lung Foundation (grant no 20200553), the Swedish Cardiac Society, the 17 Royal Swedish Academy of Sciences (grant no LM2019-0013), Women and Health 18 Foundation, Region Kronoberg (grant no 8301), The Swedish Heart and Lung Association (grant no LKH1387), Swedish Association of Clinical Physiology, and the Scandinavian 19 20 Society of Clinical Physiology; Nuclear Medicine. The study was funded in part by grants (PI Ugander) from New South Wales Health, Heart Research Australia, and the University of 21 22 Sydney. 23 **Author contributions:** TL and IPL contributed to study design, performed the data analysis, 24 wrote the first manuscript drafts, prepared the figures, and are shared first authors by equal 25 contributions. TTS curated the data, contributed to study design, performed the prediction 26 modeling, and critically revised the manuscript. MU designed the study, provided supervision, 27 and critically revised the manuscript. All authors read and approved the final version of the manuscript. 28 29 **Competing interests:** 30 TL, IPL: None TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation 31 32 consultancy using software that can quantify the advanced ECG measures used in the current 33 study. TTS and MU are owners and founders of Advanced ECG Systems, a company that is 34 developing commercial applications of advanced ECG technology used in the current study. 35 Corresponding author: Martin Ugander, martin.ugander@ki.se, Professor of Cardiac 36 37 Imaging, University of Sydney, Sydney, Australia, and Karolinska Institute, Sweden. 38

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Background**: Electrocardiographic (ECG) Heart Age conveying cardiovascular risk has been estimated by both Bayesian and artificial intelligence approaches. We hypothesized that explainable measures from the 10-second 12-lead ECG could successfully predict Bayesian ECG Heart Age. **Methods:** Advanced analysis was performed on ECGs from healthy subjects and patients with cardiovascular risk or proven heart disease. Regression models were used to predict a Bayesian 5-minute ECG Heart Age from the standard resting 10-second 12-lead ECG. The difference between 10-second ECG Heart Age and chronological age was compared. **Results**: In total, 2,771 subjects were included (n=1682 healthy volunteers, n=305 with cardiovascular risk factors, n=784 with cardiovascular disease). Overall, 10-second Heart Age showed strong agreement with the 5-minute Heart Age (R<sup>2</sup>=0.94, p<0.001, mean±SD bias 0.0±5.1 years). The difference between 10-second ECG Heart Age and chronological age was 0.0±5.7 years in healthy individuals, 7.4±7.3 years in subjects with cardiovascular risk factors (p<0.001), and 14.3±9.2 years for patients with cardiovascular disease (p<0.001). **Conclusions:** ECG Heart Age can be accurately estimated from a 10-second 12-lead ECG in a transparent and explainable fashion based on known ECG measures, without artificial intelligence techniques. The difference between ECG Heart Age and chronological age increases markedly with cardiovascular risk and disease. Keywords: vascular age; electrocardiography cardiovascular risk prediction; advanced electrocardiography; vectorcardiography

## **Background**

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Cardiovascular disease is a significant contributor to mortality, and pathological processes begin early and can progress silently for many years <sup>1-3</sup>. Many of the risk factors for developing cardiovascular disease are lifestyle-related<sup>4</sup>. Fortunately, several of these are modifiable, and risk can therefore be reduced for example by smoking cessation, dietary changes and increased physical activity<sup>5,6</sup>. To accomplish this, an individual must fully understand their risk and become motivated to act upon it. One way of communicating risks to the patient is to present the risk as a "Heart Age", which can be contrasted to the patient's chronological age. A Heart Age can either be determined by translating risk factor scores to what age that score would represent in an individual with no risk factors, or it can be based on electrocardiographic changes<sup>7-12</sup>. Describing the risk to the patient using Heart Age has been reported to reduce metabolic risk factors and may have the advantage of being easily understood by the patient<sup>11,13</sup>. A similar approach has been applied when conveying risk to smokers by describing how 'old' their lungs are, and such an approach increased the chance of smoking cessation<sup>14</sup>. Moving beyond but not excluding basic ECG measurements such as heart rate and waveform amplitudes and durations, the diagnostic output from the ECG can be further substantially improved by using combinations of advanced ECG measures from 12-lead-ECG-derived vectorcardiography and waveform complexity<sup>15-17</sup>. An accurate ECG Heart Age using advanced, 5-minute, 12-lead ECG was developed in 2014, based on Bayesian statistics9. The Bayesian approach was transparent in so much as the advanced ECG measures contributing to the ECG Heart Age were well-described. After being trained on a set of healthy individuals, this approach yielded increased ECG Heart Ages for subjects at risk of cardiovascular disease and even higher ECG Heart Ages for those with established cardiovascular disease<sup>9</sup>. However, the reliance on 5-minute, high-fidelity 12-lead ECG recordings lessens the

likelihood of widespread clinical use. If standard 10-second ECG recordings could be used instead, the clinical impact might be enhanced. Moreover, artificial intelligence has been used to estimate ECG Heart Age using the 10-second resting 12-lead ECG<sup>7,8,10</sup>. However, artificial intelligence techniques are limited by their "black box" approach, whereby the clinician does not have transparency as to the exact source(s) of the changes in the ECG that can affect an ECG Heart Age or other output <sup>18,19</sup>. Therefore, the aim of the study was to predict 5-minute ECG Heart Age from measures available by 10-second 12-lead ECG, and to compare the 10-second ECG Heart Age to chronological age in healthy subjects, subjects with cardiovascular risk factors, and patients with established cardiovascular disease. We hypothesized that 10-second 12-lead ECG recordings could accurately predict Bayesian ECG Heart Ages derived from 5-minute 12-lead ECG recordings.

## Methods

A database of de-identified patients with both 5-minute and 10-second 12-lead ECG recordings was utilized for the study<sup>9</sup>. Within that database, healthy individuals, patients at cardiovascular risk, and patients with established cardiovascular disease were included. All healthy subjects were low-risk asymptomatic volunteers with absence of any cardiovascular or systemic disease, based on clinical history and physical examination. Exclusion criteria for the healthy subjects included increased blood pressure at physical examination (≥140/90 mm Hg), treatment for hypertension or diabetes, or active smoking. Patients with established cardiovascular disease were included based on the presence of either coronary heart disease (determined by coronary angiography with at least one obstructed vessel (≥50%) in at least one major native coronary vessel or coronary graft, or, if coronary angiography was either unavailable or clinically not indicated, one or more reversible perfusion defects on 99m-Tc-tetrofosmin single-photon emission computed tomography (SPECT)<sup>20-22</sup>), left ventricular

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

hypertrophy (LVH) based on imaging evidence of at least moderate, concentric wall thickening according to guidelines of the American Society of Echocardiography<sup>23</sup>, left systolic dysfunction (left ventricular ejection fraction ≤50%) at echocardiography, cardiac magnetic resonance imaging (CMR) or SPECT, or findings suggestive of dilated/hypertrophic/ischemic cardiomyopathy at echocardiography or CMR<sup>16</sup>. Finally, subjects at cardiovascular risk were included based on the presence of cardiovascular risk factors such as hypertension or diabetes but no confirmed established cardiovascular disease<sup>9</sup>. Based on the above, three groups of study participants were included: healthy subjects, subjects at cardiovascular risk, and patients with established cardiovascular disease. By methodological design, onlyhealthy subjectswere initially included when considering optimal measures of ECG available from 10-second 12-lead ECG for predicting the 5-minute ECG Heart Age. The 10-second ECG measures considered for the prediction model included: (1) From the conventional ECG: heart rate, R-to-R, P-wave, PR, QRS, QT, QTc, and TQ interval durations, as well as the conventional ECG amplitudes and axes; (2) From the transformation of the 12-lead ECG to the Frank X, Y and Z lead vectorcardiogram (VCG) via Kors' transform<sup>24-28</sup>: the spatial means and peaks QRS-T angles, the spatial ventricular gradient and its individual QRS and T components, the spatial QRS- and T-wave axes (azimuths and elevations), waveform amplitudes and areas, including those in the three individual vectorcardiographic planes, and spatial QRS-and T-wave velocities; and (3) measures of QRS-and T-wave waveform complexity based on singular value decomposition after signal averaging<sup>29-31</sup>. For all study participants, the difference between the 10-second ECG Heart Age and the chronological age was also calculated. Results were then compared between the three groups defined above. All participants gave written informed consent. All recordings were obtained under Institutional Review Board (IRB) approvals from NASA's Johnson Space Center and

partner hospitals that fall under IRB exemptions for previously collected and de-identified data. The study was performed in accordance with the Declaration of Helsinki. Statistical analysis Continuous variables were described using mean and standard deviation (SD). The chisquared test was used to test for proportional differences between groups. Student's t test was used to compare group means. The 10-second ECG Heart Age was first derived only in the healthy subject group through a process of feature selection, via optimized stepwise procedures, of measures available from 10-s, standard-fidelity ECG recordings, first using univariable linear regression, and finally as multivariable linear regression, to best predict the 5-minute ECG Heart Age<sup>9</sup>. The best model was defined as the model with highest R<sup>2</sup> value that was also the most parsimonious, i.e., a model with statistically equal performance that incorporated a lesser number of measures was considered more parsimonious due to less proneness to over-fitting. The best model from the healthy volunteers was then applied forward to an expanded population that also included the other two groups (cardiovascular risk and cardiovascular disease, respectively), while not changing any of the included variables, and only allowing optimization of the included coefficients. The final sex-specific model was then applied across all three groups as the 10-secondECG Heart Age, and comparisons with 5-minute ECG Heart Age are presented as scatter plots and Bland-Altman plots. A two-sided p-value of 0.05 was used as to define statistical significance. Statistical analyses were performed using SAS JMP version 11.0, SAS Institute Inc, Cary, NC, USA, and R version 3.5.3R, R Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org/.

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

**Results** In total, 2,771 patients were included (n=1682 healthy volunteers, n=305 subjects with cardiovascular risk factors, n=784 with cardiovascular disease). Baseline characteristics are presented in Table 1. The ECG measures included in the final prediction models are presented in Table 2 (males) and Table 3 (females). The 10-second ECG Heart Age showed excellent agreement with the 5-minute Heart Age (R<sup>2</sup>=0.94, p<0.001, mean±SD bias 0.0±5.2 years), Figure 1. Agreement was strong for both males and females ( $R^2=0.91$ , p<0.001, and  $R^2=0.92$ , p<0.001 respectively). In healthy subjects, there was no difference in ECG Heart Age and chronological age (0.0±5.7 years). In subjects with cardiovascular risk factors, the difference was higher (7.4±7.3 years, p<0.001). Patients with cardiovascular disease showed the largest difference between ECG Heart Age and chronological age (14.3±9.2 years, p<0.001 when compared to subjects at cardiovascular risk), Figure 2. **Discussion** We found that ECG Heart Age based on measures of advanced ECG can be accurately predicted from standard resting 10-second 12-lead ECG recordings. This facilitates widespread use of ECG Heart Age in routine clinical settings, since neither specialized ECG machines nor unusually lengthy recordings are necessary. Also, if digital ECG raw data are available and the recording is of acceptable quality, ECG Heart Age can be retrospectively determined. Further, we found ECG Heart Age to be similar to chronological age in healthy individuals, while the ECG Heart Age was increasingly older with increasing cardiovascular disease status. This suggests that the ECG Heart Age is likely to provide accurate

cardiovascular risk prediction, although validation in other datasets is necessary.

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

Explainability and transparency of variables that contribute to ECG Heart Age For an estimation of Heart Age to be accurate in predicting an age that is similar to the chronological age when the heart is healthy, and increased when the heart is diseased, it is desirable that the included ECG measures change with age, and that the change is augmented with increasing cardiovascular risk or disease severity. Beyond age itself, the two ECG measures that had the strongest influence (highest t ratio) on the model were P-wave duration and spatial OT duration, and these measures fit this description well. P-wave duration increases with age<sup>32</sup>, and increased P-wave duration can be seen in advanced cardiovascular pathologies, e.g. heart failure and cardiac amyloidosis<sup>33</sup>. Similarly, QT duration increases with age<sup>34</sup>. Further, QT prolongation is associated with increased of cardiovascular risk, even beyond the rare long QT syndromes<sup>35</sup>, and with incrementally increased risk in advanced ages<sup>36</sup>. These general characteristics are also true for increased heart rate and for leftward shifting of the frontal plane QRS axis<sup>37-40</sup>. The other measures included in the score track changes in the vectorcardiographic QRS and T, and in T-wave complexity by singular value decomposition. Such changes are also known to occur in conditions associated with increased cardiovascular risk, such as hypertension and diabetes<sup>41</sup>, and in established cardiovascular disease, in which they often provide strong diagnostic and prognostic information 24-27,29-31. Notably, these changes are not easily detectable by visual interpretation of a standard 12-lead ECG. How these ECG measures can affect the ECG Heart Age is exemplified in Figure 3.

Taken together, the described ECG measures that contribute in a multivariable fashion to the

ECG Heart Age all have physiologically reasonable associations with age and disease in a

way that is transparent to the assessing clinician, thus providing important explainability to

the model.

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Differences compared to Bayesian 5-minute ECG Heart Age The original, Bayesian 5-minute ECG Heart Age requires information from measures of beatto-beat heart rate and QT variability, and of the root-mean square voltage or other aspects of high-frequency (high fidelity) components of the QRS complex 42-44. However, 10-secondduration recordings of standard fidelity do not allow for such measures, and therefore they were not included in the 10-second ECG Heart Age. However, unlike the original Bayesian 5minute ECG Heart Age, the 10-second ECG Heart Age should be derivable from any standard 12-lead ECG machine, as long as it is sufficiently equipped with software that can measure the included measures and calculate the 10-second ECG Heart Age. The presented 10-second ECG Heart Age might therefore be anticipated to contribute to more widespread clinical penetration and use. Comparison with other Heart (or Vascular) Ages Different means of expressing cardiovascular risk by translating it into a heart or vascular age have recently been published<sup>13</sup>. Attia, et al, showed that by using a deep neural network (DNN) artificial intelligence (AI) technique, a patient's chronological age could be predicted, and that if the difference between the predicted and actual age was small, prognosis was good <sup>8</sup>. When Heart Age by Attia et al's technique was older than the chronological age, the risk of future death was increased<sup>7</sup>. This corresponds well to the findings in our study that ECG Heart Age increased with increasing burden of cardiovascular risk. However, the prognostic value of the ECG Heart Age presented in the current study requires additional validation. Furthermore, another AI method similar to that of Attia et al reported similarly encouraging results 10. However, although the results of such AI studies are promising, DNN-based AI techniques are inherently problematic in several respects, especially in relation to their lack of transparency and explainability, i.e., the 'black box' of AI<sup>18,19</sup>. Without the ability to know the

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

exact features of the 12-lead ECG that are most important in a given DNN model's output, both interpretability and ethical accountability are compromised<sup>45</sup>. Moreover, it is effectively impossible for a clinician to identify, when critically evaluating the diagnostic output of a DNN-based AI model, the possible contribution to the result from methodological artifact or bias merely related to noise or to differing technical specifications between different ECG machines<sup>46</sup>. Alternatively, it is not possible to know if unanticipated results are possibly just related to excess dependency on the particular characteristics of a given DNN AI model's training set<sup>47</sup>. In addition, a major flaw in both DNN-based AI models is that the age predictions were made using datasets including individuals with both cardiovascular risk factors and established disease<sup>8,10</sup>. For ECG Heart Age to be used as a marker of cardiovascular risk, it is imperative that ECG Heart Age agrees with chronological age in healthy populations, since it is the deviations from the line of identity in this relationship that form the basis of the assumed risk increase<sup>8</sup>. Hence, we believe that the pursuit of an ECG Heart Age developed from heart-healthy subjects of varying ages, but without a black-box DNN or related AI methodology is valuable, and that the present results provide sufficient confirmation of accuracy to encourage further development. In addition, models in which the assessments were based on age predictions in healthy subjects will likely outperform models that were not. And finally, the use of more transparent regression models will also increase the ability of clinicians to better understand the origin of any unexpected result, and to thereafter relay it to the patient with a more convincing sense of trust and ethical accountability<sup>45</sup>. Limitations Using the same dataset for training and validation, our results can only be considered as proof-of-concept. Although the difference between ECG Heart Age and the subjects'

chronological age increased with increasing cardiovascular risk and/or disease, the prognostic value is unknown. Also, although ECG Heart Age was highly accurate, the precision cannot be reliably defined in this study. These aspects therefore need to be addressed in future studies.

\*\*Conclusion\*\*

We show that ECG Heart Age can be accurately, transparently, and explainably estimated from a standard 10-s, resting 12-lead ECG utilizing multiple, discrete conventional and advanced ECG measures. The difference between ECG Heart Age and subjects' chronological age increases with increasing cardiovascular risk and disease. The prognostic value of our transparent and explainable 10-second ECG Heart Age requires prospective evaluation in future studies.

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

6

7

8

(2018).

## References 1 Bergström, G. et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. Circulation 144, 916-929, doi:10.1161/circulationaha.121.055340 (2021).2 Townsend, N. et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 37, 3232-3245, doi:10.1093/eurheartj/ehw334 (2016). 3 Badimon, L. & Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Int Med 276, 618-632, doi:10.1111/joim.12296 (2014). 4 Andersson, C. & Vasan, R. S. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol 15, 230-240, doi:10.1038/nrcardio.2017.154 (2018). 5 Elliot, C. A. & Hamlin, M. J. Combined diet and physical activity is better than diet or physical activity alone at improving health outcomes for patients in New Zealand's primary care intervention. BMC Publ Health 18, 230, doi:10.1186/s12889-018-5152-z

Lim, S. S. et al. A comparative risk assessment of burden of disease and injury

attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a

2260, doi:10.1016/s0140-6736(12)61766-8 (2012).

systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224-

Ladejobi, A. O. et al. The 12-lead electrocardiogram as a biomarker of biological age.

Attia, Z. I. et al. Age and Sex Estimation Using Artificial Intelligence From Standard

Eur Heart J - Dig Health 2, 379-389, doi:10.1093/ehjdh/ztab043 (2021).

12-Lead ECGs. Circ Arrhythm Electrophysiol 12, e007284,

doi:10.1161/circep.119.007284 (2019).

296	9	Ball, R. L., Feiveson, A. H., Schlegel, T. T., Starc, V. & Dabney, A. R. Predicting
297		"heart age" using electrocardiography. J Pers Med 4, 65-78, doi:10.3390/jpm4010065
298		(2014).
299	10	Lima, E. M. et al. Deep neural network-estimated electrocardiographic age as a
300		mortality predictor. <i>Nature Commun</i> <b>12</b> , 5117, doi:10.1038/s41467-021-25351-7
301		(2021).
302	11	Lopez-Gonzalez, A. A. et al. Effectiveness of the Heart Age tool for improving
303		modifiable cardiovascular risk factors in a Southern European population: a
304		randomized trial. Eur J Prev Cardiol 22, 389-396, doi:10.1177/2047487313518479
305		(2015).
306	12	Soureti, A., Hurling, R., Murray, P., van Mechelen, W. & Cobain, M. Evaluation of a
307		cardiovascular disease risk assessment tool for the promotion of healthier lifestyles.
308		Eur J Cardiovasc Prev Rehab 17, 519-523, doi:10.1097/HJR.0b013e328337ccd3
309		(2010).
310	13	Groenewegen, K. A. et al. Vascular age to determine cardiovascular disease risk: A
311		systematic review of its concepts, definitions, and clinical applications. Eur J Prev
312		Cardiol 23, 264-274, doi:10.1177/2047487314566999 (2016).
313	14	Parkes, G., Greenhalgh, T., Griffin, M. & Dent, R. Effect on smoking quit rate of
314		telling patients their lung age: the Step2quit randomised controlled trial. BMJ 336,
315		598-600, doi:10.1136/bmj.39503.582396.25 (2008).
316	15	Maanja, M. et al. The electrical determinants of increased wall thickness and mass in
317		left ventricular hypertrophy. J Electrocardiol 58, 80-86,
318		doi:10.1016/j.jelectrocard.2019.09.024 (2020).
319	16	Schlegel, T. T. et al. Accuracy of advanced versus strictly conventional 12-lead ECG
320		for detection and screening of coronary artery disease, left ventricular hypertrophy and

321 left ventricular systolic dysfunction. BMC Cardiovasc Disord 10, 28, 322 doi:10.1186/1471-2261-10-28 (2010). 323 17 Johnson, K. et al. Advanced Electrocardiography Identifies Left Ventricular Systolic 324 Dysfunction in Non-Ischemic Cardiomyopathy and Tracks Serial Change over Time. J 325 Cardiovasc Dev Dis 2, 93-107, doi:10.3390/jcdd2020093 (2015). 326 18 Gladding, P. A., Hewitt, W. & Schlegel, T. T. Going deep with ecg and aortic 327 stenosis: Touchdown or incomplete pass? J Am Heart Assoc 9, e016193-e016193, 328 doi:10.1161/JAHA.120.016193 (2020). 329 19 The Lancet Respiratory Medicine, L. R. M. Opening the black box of machine 330 learning. Lance Respir Med 6, 801-801, doi:10.1016/S2213-2600(18)30425-9 (2018). 331 20 Vrtovec, B., Sinkovec, M., Starc, V., Radovancevic, B. & Schlegel, T. T. Coronary 332 artery disease alters ventricular repolarization dynamics in type 2 diabetes. *Pacing* 333 Clin Electrophysiol **28 Suppl 1**, S178-181, doi:10.1111/j.1540-8159.2005.00076.x 334 (2005).335 21 Persson, E., Carlsson, M., Palmer, J., Pahlm, O. & Arheden, H. Evaluation of left 336 ventricular volumes and ejection fraction by automated gated myocardial SPECT 337 versus cardiovascular magnetic resonance. Clin Physiol Funct Imaging 25, 135-141, 338 doi:10.1111/j.1475-097X.2005.00599.x (2005). 339 22 Trägårdh, E. et al. High-frequency electrocardiogram analysis in the ability to predict 340 reversible perfusion defects during adenosine myocardial perfusion imaging. J 341 Electrocardiol40, 510-514, doi:10.1016/j.jelectrocard.2007.03.242 (2007). 342 23 Lang, R. M. et al. Recommendations for cardiac chamber quantification by 343 echocardiography in adults: an update from the American Society of 344 Echocardiography and the European Association of Cardiovascular Imaging. Eur 345 *Heart J Cardiovasc maging* **16**, 233-270, doi:10.1093/ehjci/jev014 (2015).

346	24	Yamazaki, T., Froelicher, V. F., Myers, J., Chun, S. & Wang, P. Spatial QRS-T angle
347		predicts cardiac death in a clinical population. Heart rhythm 2, 73-78,
348		doi:10.1016/j.hrthm.2004.10.040 (2005).
349	25	Fayn, J., Rubel, P., Pahlm, O. & Wagner, G. S. Improvement of the detection of
350		myocardial ischemia thanks to information technologies. Int J Cardiol 120, 172-180,
351		doi:10.1016/j.ijcard.2006.09.025 (2006).
352	26	Kardys, I. et al. Spatial QRS-T angle predicts cardiac death in a general population.
353		European heart journal <b>24</b> , 1357-1364, doi:10.1016/S0195-668X(03)00203-3 (2003).
354	27	Horinaka, S. et al. Ventricular gradient variability. New ECG method for detection of
355		ischemic heart disease. J Electrocardiol 28, 177-183, doi:10.1016/S0022-
356		0736(05)80255-9 (1995).
357	28	Kors, J. A., van Herpen, G., Sittig, A. C. & van Bemmel, J. H. Reconstruction of the
358		Frank vectorcardiogram from standard electrocardiographic leads: diagnostic
359		comparison of different methods. Eur Heart J 11, 1083-1092 (1990).
360	29	Zabel, M. et al. Analysis of T-wave morphology from the 12-lead electrocardiogram
361		for prediction of long-term prognosis in male US veterans. Circulation 105, 1066-
362		1070, doi:10.1161/hc0902.104598 (2002).
363	30	Okin, P. M. et al. Repolarization Abnormality for Prediction of All-Cause and
364		Cardiovascular Mortality in American Indians: The Strong Heart Study. $J$ $Cardiovasc$
365		Electrophysiol 16, 945-951, doi:10.1111/j.1540-8167.2005.40808.x (2005).
366	31	Priori, S. G. et al. Evaluation of the spatial aspects of T-wave complexity in the long-
367		QT syndrome. <i>Circulation</i> <b>96</b> , 3006-3012, doi:10.1161/01.CIR.96.9.3006 (1997).
368	32	Chhabra, L., Devadoss, R., Chaubey, V. K. & Spodick, D. H. Interatrial Block in the
369		Modern Era. Curr Cardiol Rev10, 181-189,
370		doi:10.2174/1573403X10666140514101748 (2014).

371	33	Lindow, T. & Lindqvist, P. The Prevalence of Advanced Interatrial Block and Its
372		Relationship to Left Atrial Function in Patients with Transthyretin Cardiac
373		Amyloidosis. <i>J Clin Med</i> <b>10</b> , doi:10.3390/jcm10132764 (2021).
374	34	Rautaharju, P. M., Mason, J. W. & Akiyama, T. New age- and sex-specific criteria for
375		QT prolongation based on rate correction formulas that minimize bias at the upper
376		normal limits. <i>Int J Cardiol</i> <b>174</b> , 535-540, doi:10.1016/j.ijcard.2014.04.133 (2014).
377	35	Shah, S. R., Park, K. & Alweis, R. Long QT Syndrome: A Comprehensive Review of
378		the Literature and Current Evidence. Curr Prob Cardiol 44, 92-106,
379		doi:10.1016/j.cpcardiol.2018.04.002 (2019).
380	36	Nielsen, J. B. et al. Risk prediction of cardiovascular death based on the QTc interval:
381		evaluating age and gender differences in a large primary care population. Eur Heart J
382		35, 1335-1344, doi:10.1093/eurheartj/ehu081 (2014).
383	37	Goorakani, Y. et al. Correlation of resting heart rate with anthropometric factors and
384		serum biomarkers in a population-based study: Fasa PERSIAN cohort study. BMC
385		Cardiovas Disord 20, 319-319, doi:10.1186/s12872-020-01594-y (2020).
386	38	Ogliari, G. et al. Resting heart rate, heart rate variability and functional decline in old
387		age. Can Med Assoc J 187, E442-e449, doi:10.1503/cmaj.150462 (2015).
388	39	Morcet, J. F., Safar, M., Thomas, F., Guize, L. & Benetos, A. Associations between
389		heart rate and other risk factors in a large French population. J Hyperten s17, 1671-
390		1676, doi:10.1097/00004872-199917120-00003 (1999).
391	40	Evans, J. G., Prior, I. A. & Tunbridge, W. M. Age-associated change in QRS axis:
392		intrinsic or extrinsic ageing? Gerontology28, 132-137, doi:10.1159/000212523
393		(1982).

394	41	Bergfeldt, L. et al. Spatial peak and mean QRS-T angles: A comparison of similar but
395		different emerging risk factors for cardiac death. J Electrocardiol61, 112-120,
396		doi:10.1016/j.jelectrocard.2020.05.013 (2020).
397	42	Ringborn, M. M. D. et al. Comparison of high-frequency QRS components and ST-
398		segment elevation to detect and quantify acute myocardial ischemia. J Electrocardiol
399		<b>43</b> , 113-120, doi:10.1016/j.jelectrocard.2009.11.009 (2010).
400	43	Trägårdh, E., Pahlm, O., Wagner, G. S. & Pettersson, J. Reduced high-frequency QRS
401		components in patients with ischemic heart disease compared to normal subjects. $J$
402		Electrocardiol 37, 157-162, doi:10.1016/j.jelectrocard.2004.02.004 (2004).
403	44	Schlegel, T. T. et al. Real-Time 12-Lead High-Frequency QRS Electrocardiography
404		for Enhanced Detection of Myocardial Ischemia and Coronary Artery Disease. Mayo
405		Clin Proc 79, 339-350, doi:10.4065/79.3.339 (2004).
406	45	Yoon, C. H., Torrance, R. & Scheinerman, N. Machine learning in medicine: should
407		the pursuit of enhanced interpretability be abandoned? J Med Ethics,
408		doi:10.1136/medethics-2020-107102 (2021).
409	46	Brisk, R. et al. The effect of confounding data features on a deep learning algorithm to
410		predict complete coronary occlusion in a retrospective observational setting. Eur
411		Heart J - Dig Health 2, 127-134, doi:10.1093/ehjdh/ztab002 (2021).
412	47	Siontis, K. C. et al. Use of Artificial Intelligence Tools Across Different Clinical
413		Settings: A Cautionary Tale. Circ Cardiovasc Qual Outcomes 14, e008153,
414		doi:10.1161/circoutcomes.121.008153 (2021).
415		
416		
416		
417		

Table 1. Baseline characteristics

	All (n=2,771)	Healthy (n=1,682)	Subjects at CV risk (n=305)	Patients with CV disease (n=784)	p
Age, years	46.2 (16.0)	38.6 13.0)	54.8 (11.2)	59.0 (13.2)	< 0.001
Male sex, n (%)	1645 (59.4)	999 (59.4)	163 (53.4)	483 (61.6)	0.048
5-minute ECG Heart Age, years	51.1 (21.7)	38.3 14.1)	61.9 (13.2)	74.2 (15.6)	< 0.001
CAD, n (%)	421 (15.2)	-	-	421 (53.7)	-
ICM, n (%)	120 (4.3)	-	-	120 (15.3)	-
HCM, n (%)	92 (3.3)	-	-	92 (11.7)	-
LVH, n (%)	96 (3.5)	-	-	96 (12.2)	-
NICM, n (%)	53 (1.9)	-	-	53 (6.8)	-

Age and 5-minute ECG Heart Age are presented as mean (standard deviation). Abbreviations: CAD: coronary artery disease; ICM: ischemic cardiomyopathy; HCM: hypertrophic cardiomyopathy; LVH: left ventricular hypertrophy; NICM: non-ischemic cardiomyopathy

**Table 2.** Measures included in the 10-second ECG Heart Age (male patients)

Measure	Estimate	Standard error	t ratio
(Intercept)	-60.575	2.353	-25.73
Age, years	0.820	0.007	113.73
P-wave duration, ms	0.288	0.007	39.99
Spatial QT interval, ms	0.081	0.004	22.86
Heart rate, min <sup>-1</sup>	0.242	0.012	20.02
QRS max amplitude in VCG lead Y, $\mu V$	-0.007	0.000	-18.20
Frontal plane QRS axis, radians	-5.834	0.395	-14.75
T-wave complexity, Ln $\Sigma$ (EV3:8) / (EV1–EV2), unitless	2.152	0.164	13.12
Spatial ventricular gradient minus Spatial mean QRS, $mV*s$	-55.841	4.464	-12.51
Male sex (value=1)	1.996	0.215	9.27
QRS RMS in VCG vector magnitude lead, mV	10.315	1.612	6.40
QRS average spatial velocity in VCG vector magnitude lead, mV/s	0.106	0.017	6.30
Portion of QRS loop in posterior superior quadrant of 0.033 0.009 3.55  left sagittal plane by VCG, %  Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square			

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

**Table 3.** Measures included in the 10-second ECG Heart Age (female patients)

Measure	Estimate	Standard error	t ratio
(Intercept)	-70.477	2.662	-26.47
Age, years	0.850	0.008	104.26
P-wave duration, ms	0.331	0.008	40.73
Spatial QT interval, ms	0.095	0.004	23.58
Heart rate, min <sup>-1</sup>	0.281	0.014	20.57
QRS max amplitude in VCG lead Y, $\mu V$	-0.009	0.000	-18.54
Frontal plane QRS axis, radians	-6.354	0.447	-14.21
Spatial ventricular gradient minus Spatial mean QRS, $mV*_S$	-67.642	5.049	-13.40
T-wave complexity, Ln $\Sigma$ (EV3:8) / (EV1–EV2), unitless	2.359	0.185	12.72
QRS RMS in VCG vector magnitude lead,mV	11.701	1.822	6.42
QRS average spatial velocity in VCG vector magnitude lead, mV/s	0.116	0.019	6.10
Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, %	0.034	0.010	3.22

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460


461


462

463

**Figure 1.** Left panel: Scatter plot showing the relation between the 10-second ECG Heart Age and the 5-minute ECG Heart Age in all participants. The R<sup>2</sup> value was 0.94 (p<0.001). Right panel: Bland-Altman plot showing the difference between the 10-second and 5-minute ECG Heart Age in relation to the mean of both ECG Heart Ages. The agreement between methods is strong, with minimal deviation from the identity line (dashed) or bias  $(0.0\pm5.2 \text{ years})$ . Figure 2. Panel A: The difference between the 10-second ECG Heart Age and chronological age in healthy subjects (left, dark green), subjects at cardiovascular (CV) risk (middle, light blue), and patients with CV disease (right, yellow). On average, there is no difference between ECG Heart Age and chronological age in healthy subjects. ECG Heart Age is higher in subjects at CV risk, and highest for those with overt CV disease. Panel B: Scatter plots showing the relationship between the 10-second ECG Heart Age and chronological age in healthy subjects (left, dark green), subjects at CV risk (middle, light blue), and patients with CV disease (right, yellow). The dashed diagonal line is the identity line, i.e. indicating no difference between ECG Heart Age and chronological age. **Figure 3.** Example of the transparency and explainability of the ECG Heart Age from two subjects with equal chronological age but different ECG Heart Ages, illustrated by a commensurately aged female heart, but a disproportionately aged male heart. The ECG measures for each of the two patients are shown in the table in the middle of the figure, presented in the order of the relative strength (strongest first, based on t ratio [not shown]) of contribution to the ECG Heart Age. Notably, P-wave duration is markedly different between these two patients, and heart rate is higher for the male than the female, helping drive the ECG Heart Age higher in the male. The R-wave amplitude in lead Y is also much larger in the

female, and the difference between the spatial ventricular gradient and the spatial mean QRS in the female is also larger, likely due to preserved T-wave amplitudes, contributing to her relatively younger ECG Heart Age. Furthermore, likely due to ischemic myocardial injuries, T-wave complexity is increased in the male, suggesting that increased myocardial repolarization heterogeneity also contributes to driving ECG Heart Age higher in the male, in spite of his shorter QT interval.









60-year old, healthy female without cardiovascular risk factors or medications

90 ms

55/min

835 µV

0.58 radians

0.038 mV\*s

-1.92

0.43 mV

39.1 mV/s

12.7%

60-year old male with heart failure following myocardial infarction

## **ECG** measures

P-wave duration	
Spotial OT intorval	

447 ms

Spatial QT interval Heart rate

QRS max amplitude in VCG lead Y Frontal plane QRS axis

Spatial ventricular gradient - spatial mean QRS T-wave complexity, Ln QRS RMS in VCG vector magnitude lead

QRS average spatial velocity in vector magnitude lead Portion of QRS loop in posterior superior quadrant of left sagital plane by VCG



148 ms

380 ms 70/min 299 µV

0.64 radians 0.003 mV\*s 1.21

23.5 mV/s 25.2% **ECG HEART AGE** 79 years

0.31 mV

